Search

Search Constraints

You searched for: Author/Creator Elena, Chiara

Search Results

2. A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. (16th August 2014)

3. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Issue 4 (30th October 2013)

4. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Issue 4 (30th October 2013)

5. Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study. Issue 10 (10th September 2015)

6. Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real‐life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. Issue 3 (17th April 2019)

7. Beyond the comfort zone of deep molecular response: discontinuation in major molecular response chronic myeloid leukemia. Issue 13 (10th November 2019)

8. Bosutinib in the real‐life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine‐kinase inhibitors. Issue 3 (13th March 2021)

9. Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second‐generation tyrosine kinase inhibitors in the real‐life practice: Identification of risk factors and the role of prophylaxis. Issue 7 (28th April 2018)